Jpmorgan Chase & CO Lucid Diagnostics Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LUCD
# of Institutions
34Shares Held
2.12MCall Options Held
0Put Options Held
0-
Luminus Management LLC Houston, TX726KShares$762,1160.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA561KShares$588,9600.0% of portfolio
-
Geode Capital Management, LLC Boston, MA214KShares$224,2170.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT126KShares$132,6800.01% of portfolio
-
Lido Advisors, LLC Los Angeles, CA100KShares$105,0160.0% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $40.5M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...